Enanta Pharmaceuticals | ENTA - Eigenkapital Und Reserven





Eigenkapital Und Reserven Veränderung Datum
AbbVie USD -6.66B 3.39B 2026-03
Amgen USD 9.19B 532M 2026-03
Anika Therapeutics USD 133.9M 9.56M 2026-03
Arrowhead Research USD 613.98M 45.56M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
BioCryst Pharmaceuticals USD -553.84M 434.69M 2026-03
Biogen USD 18.65B 394.9M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Gilead Sciences USD 23.52B 897M 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Halozyme Therapeutics USD 219.64M 170.82M 2026-03
Heron Therapeutics USD 9.14M 4.15M 2026-03
Immunic USD 151.23M 157.91M 2026-03
Incyte USD 5.62B 455.37M 2026-03
Insmed USD 704.85M 34.12M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
J&J USD 81.19B 358M 2026-03
Karyopharm Therapeutics USD -292.93M 23.67M 2025-12
Ligand Pharmaceuticals USD 997.32M 19.89M 2026-03
Merck USD 45.88B 6.73B 2026-03
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 38.93B 7.2B 2026-03
Novavax USD -144.76M 17.01M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
PTC Therapeutics USD -180.46M 24.85M 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03